Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
NSC Norfolk Southern Corp
WM Waste Management Inc
ITOS Iteos Therapeutics Inc
CCLD CareCloud Inc
JEF Jefferies Financial Group Inc
RSASF Resaas Services Inc
VRNT Verint Systems Inc
TRHC Tabula Rasa HealthCare Inc
ILMN Illumina Inc

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Day's Change
-9.16 (-1.17%)
B/A Size
Day's High
Day's Low
(Below Average)

Today's volume of 590,738 shares is on pace to be lower than REGN's 10-day average volume of 724,147 shares.


House passes Inflation Reduction Act: What Democrats' bill does for climate, drug prices and taxes

10:52 am ET August 13, 2022 (MarketWatch)

Robert SchroederVictor Reklaitis

Measure is expected to get signed into law quickly by President Joe Biden

Democrats' Inflation Reduction Act passed the House of Representatives in a 220-207 vote on Friday after clearing the Senate last weekend, and with it, some big changes could be coming to key sectors of the U.S. economy.

The measure, though a slimmed-down version of President Joe Biden's Build Back Better proposal, would pump billions of dollars into climate and healthcare programs, while levying new taxes on big companies and stock buybacks to pay for it all.

Below is a look at some of the key provisions of the bill, which passed the Senate in a 51-50 vote on Sunday, as Vice President Kamala Harris broke a tie. No Republicans in the Senate or House voted for it, as the GOP argued the measure wouldn't live up to its name as an inflation-fighting measure.

Related:Inflation Reduction Act wouldn't lower prices by all that much, analysts say

And see:Will the Inflation Reduction Act actually reduce inflation?

The legislation is expected to get signed into law quickly by Biden.


The bill includes $369 billion for climate and energy provisions and would accelerate the U.S.'s transition away from fossil fuels.

As MarketWatch reported, the bill's energy and climate-focused (ICLN) incentives are peppered with rebates and tax credits that will directly impact households. They address heat pumps, appliance efficiency, solar panels, electric vehicles (TSLA)(F) and more.

Now read:Here's how the Inflation Reduction Act's rebates and tax credits for heat pumps and solar can lower your energy bill

Sen. Joe Manchin, a key West Virginia Democrat, also said he'd secured a side agreement to advance an energy-permitting reform package before the end of September -- which could make it easier to build pipelines.

Investors earlier this week saw an immediate impact of the Senate's advancing the bill, as shares of solar (FSLR), EV and fuel-cell (FCEL) companies all rallied Monday.

See:Fuel cell, EV and solar stocks rally as climate bill makes 'alternative' energy more 'in the money'


Medicare would be able to negotiate the cost of some prescription drugs with pharmaceutical companies (PJP) under the deal -- a provision that's been blasted by the industry, which says the measure would throttle innovation.

Retirement:Thanks to the Inflation Reduction Act, Medicare is on track to negotiate drug prices -- what it means for you

The bill also caps out-of-pocket drug costs for Americans on Medicare at $2,000 a year, beginning in 2025.

Before the deal, 13 million people were facing higher health-insurance premiums next year. Now, Affordable Care Act subsidies will be extended for three years, sparing millions of Americans.

Democrats' goal of lowering insulin prices for Medicare is expected to become law. But during a lengthy process to amend the bill over the weekend, Senate Republicans blocked a $35 price cap on insulin costs for patients on private insurance.

Now see:Insulin cost remains 'catastrophic' for millions of Americans, despite Inflation Reduction Act capping Medicare copay at $35


The bill's 15% minimum tax for large companies that pay little or nothing in income taxes could hit big names like Amazon (AMZN) and Tesla, Barron's reported. The tax would apply to those that have averaged $1 billion of adjusted pretax profit in the past three years.

Barron's:Tesla and 9 other companies that would take a hit from a 15% minimum corporate tax

While the bill doesn't directly raise taxes on middle-class households, Republicans have touted analysis saying the bill's tax increases will hit working families with "higher prices, fewer jobs and lower wages."

The Inflation Reduction Act also contains a 1% tax on stock buybacks. Some analysts, reported the Wall Street Journal, said they don't expect the tax to dent companies' enthusiasm for repurchases.

Market Extra:Stock buybacks near $800 billion this year after hitting all-time record

Democrats dropped a plan to close the so-called carried interest loophole in the face of opposition from Sen. Kyrsten Sinema, an Arizona Democrat. But, after pressure from Sinema, the party agreed to protect companies owned by the private equity industry from the new minimum tax.

Now read:An investor's guide to the Inflation Reduction Act -- how to prepare your portfolio if the bill becomes law

This is an updated version of a report first published on Aug. 8, 2022.

-Robert Schroeder


(END) Dow Jones Newswires

August 13, 2022 10:52 ET (14:52 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.